Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Exclusion Criteria

• •Patients who are currently receiving cytotoxic chemotherapy or radiation therapy, or who have received that therapy within the preceding 4 weeks.
• •Patients who are currently receiving investigational agents, or who have received investigational agents within the preceding 30 days.
• •Patients with known or suspected allergies to any component of the vaccine.
• •Patients receiving the following medications at study entry or within 30 days are excluded:
• •* Allergy desensitization injections
• •* Corticosteroids, administered parenterally or orally.
• •Topical corticosteroids are acceptable, Any growth factors, Interferons, Interleukin 2 (IL-2).
• •Pregnancy or the possibility of becoming pregnant during vaccine administration.
• •Female patients of child-bearing potential must have a negative pregnancy test (urinary or serum beta-HCG) prior to administration of the first vaccine dose.
• •Males and females must agree, in the consent form, to use effective birth control methods during the course of vaccination. This is consistent with existing standards of practice for vaccine and chemotherapy protocols.
• •Patients in whom there is a medical contraindication or other potential medical problem in complying with the requirements of the protocol, in the opinion of the investigator.
• •Patients classified according to the New York Heart Association classification system as having Class II, III or IV heart disease.
• •Patients with active connective tissue disease requiring medications, or other severe autoimmune disease.
• •Patients who are actively hyperthyroid.
• •Patients with uncontrolled diabetes.
• •Patients with known allergies to penicillin, streptomycin, and amphotericin B.